ArticleOncotarget2017
Clinicopathological characteristics of
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Efficacy of selpercatinib as a first-line treatment forJournal of comparative effectiveness research · 2026Trial
- Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.Nature medicine · 2024Trial
- Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.Translational oncology · 2026Article
- Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients.ACS pharmacology & translational science · 2026Review
- Review
- Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.Current oncology (Toronto, Ont.) · 2025Review
- Article
- Lung adenocarcinoma patients withHeliyon · 2024Article
- Clinical outcomes ofEcancermedicalscience · 2024Article
- Modern therapies of nonsmall cell lung cancer.Journal of applied genetics · 2023Review
- Long-Term Efficacy and Safety of Entrectinib inJTO clinical and research reports · 2022Article
- Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- RET Inhibitors in Non-Small-Cell Lung Cancer.Cancers · 2021Review
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or MetastaticJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.BMC cancer · 2021Observational
- Simultaneous analysis ofTranslational lung cancer research · 2021Article
- Clinical characteristics of patients withTranslational cancer research · 2020Article
- Emerging non-invasive detection methodologies for lung cancer.Oncology letters · 2020Review
- Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas .Vaccines · 2020Article
- Brain metastases in oncogene-driven non-small cell lung cancer.Translational lung cancer research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted therapies have substantially changed the management of non-small cell lung cancer (NSCLC) patients with driver oncogenes. Given the high frequency,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.